These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2005-003971-19 Clinical study to evaluate the ability of MUSE to increase erectile function in post-radical prostatectomy patients - Randomised, controlled, open study with two parallel groups comparing MUSE 250 µg... 2008-08-18 due-trials
Reported results 2006-001510-32 Active-Controlled Trial of the Safety and Tolerability of MP03-33 in Patients with Chronic Allergic or Nonallergic Rhinitis 2007-12-28 due-trials
Reported results 2007-002553-23 Clinical trial to assess the protective effect of the fixed drug combination of disodium cromoglycate plus reproterol in comparison to the single components and placebo in adults with exercise induced... 2008-10-30 due-trials
Reported results 2007-004884-24 Long-term effects of Aldara® 5% cream and Solaraze® 3% gel in the treatment of actinic keratoses on the face or scalp (LEIDA) 2012-11-20 due-trials
Ongoing 2008-002501-39 Quality of life of patients with actinic keratoses and/or a superficial basal cell carcinoma treated with Imiquimod 5% cream. not-yet-due
Reported results 2009-012083-14 An Open-Label Multicenter Study of the Effects of Remission Maintenance Therapy with Ceplene (Histamine Dihydrochloride) Given in Conjunction with Low-Dose Interleukin-2 (IL-2 Proleukin) on Immune Res... 2014-06-04 due-trials
Reported results 2009-014441-93 Clinical trial to assess the efficacy of the fixed combination product Tepilta® in the treatment of radiation-induced oesophagitis compared to its active ingredients oxetacaine and antacids, and to p... 2017-01-18 due-trials
Reported results 2010-022054-16 Long-term effects of Aldara® 5% cream and Solaraze® 3% gel in the treatment of actinic keratoses on the face or scalp with respect to the risk of progression to in-situ and invasive squamous cell carc... 2015-03-27 due-trials
Trial is outside EEC, and reported results 2011-001369-42 Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients with Seasonal Aller... bad-data
Trial is outside EEC, and reported results 2011-001370-26 Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients with Seasonal Aller... bad-data
Trial is outside EEC, and reported results 2011-001371-39 Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray and Fluticasone Propionate Nasal Spray in the Treatment of Patients with Seasonal Allerg... bad-data
Reported results 2011-001965-42 A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP, PHASE III STUDY OF THE EFFICACY AND SAFETY OF HERCULES PLUS TAXANE VERSUS HERCEPTIN® PLUS TAXANE AS FIRST LINE THERAPY IN PATIENTS WITH HER2-PO... 2018-08-03 due-trials
Reported results 2012-002682-36 Comparison of the Efficacy of Diclofenac Sodium Topical Gel, 1% (Mylan) to Voltaren® Gel, 1% (Novartis US) and Placebo in Adult Subjects with Knee Osteoarthritis 2013-08-30 due-trials
Reported results 2014-000747-32 AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, PARALLEL-GROUP CLINICAL TRIAL COMPARING THE EFFICACY AND SAFETY OF MYLAN’S INSULIN GLARGINE WITH LANTUS® IN TYPE 1 DIABETES MELLITUS PATIENTS 2016-07-07 due-trials
Reported results 2014-000881-23 AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, PARALLEL GROUP CLINICAL TRIAL COMPARING THE EFFICACY AND SAFETY OF MYLAN’S INSULIN GLARGINE WITH LANTUS® IN TYPE 2 DIABETES MELLITUS PATIENTS 2015-12-24 due-trials
Ongoing 2014-001088-11 Academic study on the effects of MP 29-02 nasal spray on inflammatory mediators in allergic rhinitis not-yet-due
Completed, but no date, and reported results 2014-001165-27 A Randomized, Double-Blind, Parallel Group 24 Week Placebo-Controlled Efficacy and Safety Study with a 28 Week Long Term Extension, of Nebulized Fluticasone Propionate (FP) /Formoterol Fumarate (FF) C... bad-data
Reported results Terminated 2014-001916-20 A Randomized, Double-Blind, Parallel Group 24 Week Placebo-Controlled Efficacy and Safety Study with a 28 Week Long Term Extension, of Nebulized Fluticasone Propionate (FP) /Formoterol Fumarate (FF) C... 2015-02-02 due-trials
Reported results 2014-002324-27 Multicenter, Double-Blind, Randomized, Comparative Efficacy and Safety Study of MYL 1401H and European Sourced Neulasta® in Stage II/III Breast Cancer Patients Receiving Neoadjuvant or Adjuvant Chemot... 2016-02-09 due-trials
Reported results 2014-003420-46 Multicenter, Double-Blind, Randomized, 2-Arm, Parallel-Group, Equivalence Study Evaluating Efficacy and Safety Similarity of Mylan Adalimumab (MYL-1401A) Compared With Humira® in Subjects With Moderat... 2017-03-06 due-trials
Exempt, with results 2015-000463-13 AN OPEN STUDY TO ASSESS THE ROBUSTNESS OF THE CRC749 DEVICE BY PHARMACEUTICAL PERFORMANCE FOLLOWING TWICE DAILY DOSING OF MGR001 ADMINISTERED VIA ORAL INHALATION IN SUBJECTS WITH ASTHMA OR CHRONIC OBS... 2015-06-12 not-yet-due
Reported results 2015-004353-40 AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, PARALLEL-GROUP CLINICAL TRIAL COMPARING THE EFFICACY AND SAFETY OF MYLAN’S INSULIN GLARGINE WITH LANTUS® IN TYPE 1 DIABETES MELLITUS PATIENTS: AN EXTENSION STU... 2017-03-10 due-trials
Reported results 2015-005141-32 Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous No... 2019-11-22 due-trials
Other 2017-003073-33 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Compare the Anti-Depressive Efficacy and Safety of Samyr® Tablet versus Placebo Tablet on top of Adjunctive Antide... not-yet-due
Other 2017-003074-14 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-center Study to Compare the Anti-Depressive Efficacy and Safety of Samyr¿ IM versus Placebo IM as an Enhancer Adjunctive to Antide... not-yet-due
Reported results 2017-004358-40 A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects with Diabetic Macular Edema 2021-09-10 due-trials
Reported results 2019-000694-24 Evaluation of the antiseptic activity of 4 different modes of application of a 5% alcoholic povidone-iodine product (Bétadine® Alcoolique 5%) EVALUATION DE L'ACTIVITE ANTISEPTIQUE D'UN PRODUIT ALCO... 2020-09-07 due-trials
Not reported 2021-006015-29 A Multicenter, Randomized, Blinded, Parallel Group, Interchangeability Study in Moderate to Severe Chronic Plaque Psoriasis evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity Between Su... 2023-10-19 due-trials
Completed, report not yet due 2022-003219-26 An open-label, phase II, dose-finding study of three dose strengths of MR-130A-01 contraceptive transdermal patch containing norelgestromin (NGMN) in healthy pre-menopausal women 2024-01-18 not-yet-due

Related organisations

Over time organisations can merge, or split.

We think Mylan is now effectively part of Viatris.